4.335SEK+1.40%Mkt Cap: 801.05M SEKP/E: —Last update: 2026-06-01
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposit…
Industry Peers
Drug Manufacturers - Specialty & Generic150.78BSEKP/E 166.4
58.93BTRY—
56.89BEURP/E 22.4
32.78BPLNP/E 21.4
23.20BUSDP/E 20.2
18.39BUSD—
16.21BUSDP/E 24.8
13.00BTRY—
Indicators:|
Key Statistics
Company
Market Cap801.05M SEK
Enterprise Value717.93M SEK
Revenue (TTM)54.41M SEK
Gross Profit55.94M SEK
Net Income (TTM)-11.39M SEK
Revenue/Share0.3360 SEK
Last Price4.335 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees16
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)19.43
PEG—
EV/EBITDA-98.06
EV/Revenue13.20
P/S14.52
P/B6.85
EPS (TTM)-0.09
EPS (Forward)0.22
52W Range
1.40082% of range5.000
52W High5.000 SEK
52W Low1.400 SEK
Profitability
Gross Margin154.74%
Oper. Margin-222.20%
EBITDA Margin-13.46%
Profit Margin-31.50%
ROE-11.22%
ROA-8.24%
Growth
Revenue Growth-20.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.46M SEK
CapEx (TTM)24.75M SEK
FCF Margin2.87%
FCF Yield0.19%
Net Debt-72.03M SEK
Net Debt/EBITDA9.84
Balance Sheet
Debt/Equity0.02
Current Ratio2.06
Quick Ratio2.06
Book Value/Sh0.6240 SEK
Cash/Share0.3950 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.184.79M
Float140.01M
Insiders43.63%
Institutions2.78%
Technical
SMA 503.721 (+16.5%)
SMA 2003.048 (+42.2%)
Beta1.75
S&P 52W Chg27.70%
Avg Vol (30d)572.24K
Avg Vol (10d)542.99K
Technical Indicators
RSI (14)73.1
MACD0.0822
MACD Signal0.0081
MACD Hist.+0.0741
BB Upper4.106 SEK
BB Middle3.674 SEK
BB Lower3.242 SEK
BB Width23.52%
ATR (14)0.2241 SEK
Vol Ratio (20d)1.42x